Home›Tesamorelin›Legal status
Educational — Not Legal AdviceReviewed
Is Tesamorelin legal? FDA status and US regulatory standing
Current status
FDA-approved. Tesamorelin is an FDA-approved drug (status recorded ).
Primary source: www.accessdata.fda.gov
Federal legal status
FDA approval status
Tesamorelin is an FDA-approved drug. FDA-approved GHRH analog. Brand: Egrifta SV (NDA 022505, Nov 2010). Indicated for excess abdominal fat in HIV lipodystrophy. Prescription only. Daily subcutaneous injection.
Also known as
Egrifta · TH9507
Status history
- Tesamorelin is an FDA-approved drug. [source]
Frequently asked questions
- Is Tesamorelin FDA approved?
- Tesamorelin is an FDA-approved drug (status recorded 2010-11-10). Primary source linked on this page.
- Can doctors prescribe Tesamorelin?
- Tesamorelin is listed as prescription-availability in the PeptideBase library. Prescribing rules vary by state and prescriber licensure — consult a licensed clinician.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Content review: Regulatory status is sourced from the linked primary records and reviewed by the PeptideBase editorial team. This page is educational — not legal or medical advice. Last reviewed: .